Why Choose Between Wegovy and Mounjaro at EverydayMeds?
Moving From Wegovy to Mounjaro: Understanding the Key Differences
When considering moving from Wegovy to Mounjaro, the fundamental difference lies in their mechanisms of action. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone to reduce appetite and promote satiety. Mounjaro, however, contains tirzepatide — a dual agonist that targets both GIP and GLP-1 receptors, potentially offering a broader hormonal approach to appetite regulation. This dual mechanism may explain why some patients consider transitioning between treatments, though both are prescription-only medicines requiring clinical assessment.
The decision between moving from Wegovy to Mounjaro often comes down to individual response and tolerability. Some patients find Wegovy's single GLP-1 action suits their needs perfectly, whilst others may benefit from Mounjaro's dual receptor approach. Both treatments require dose escalation protocols and work alongside lifestyle modifications. EverydayMeds offers both options through our GPhC #9012878 registered pharmacy, allowing your prescriber to determine which treatment aligns best with your weight management goals and medical history.
Wegovy vs Mounjaro Pricing: Complete Cost Comparison
Understanding the pricing differences when moving from Wegovy to Mounjaro helps inform your treatment decision. Wegovy follows a 5-dose escalation: 0.25mg (£79.99), 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), and 2.4mg maintenance (£209.99). These prices reflect the final cost after applying discount codes FIRST40 for new customers or DOSE25 for returning patients at checkout. Our Getting Started bundles like the Intro Duo (0.25mg & 0.5mg) cost £169.99, providing convenient two-month starter supply.
Mounjaro pricing differs due to its 6-dose protocol ranging from 2.5mg to 15mg maintenance doses. When moving from Wegovy to Mounjaro, patients should factor in the extended escalation period and different dose intervals. Both treatments are available through our express prescriber review service, with standard 3 working days or 24-hour express assessment. All orders include next-day cold-chain delivery to ensure temperature-controlled storage throughout transit, maintaining each treatment's efficacy from our pharmacy to your door.
Clinical Evidence for Moving From Wegovy to Mounjaro Decisions
The STEP trials demonstrated that patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks, with STEP 5 showing sustained clinically studied weight loss at 2 years (Wilding et al., NEJM, 2021). These results established semaglutide as an effective prescription-only medicine for weight management in adults with BMI ≥30 or BMI ≥27 with comorbidities. The SELECT cardiovascular outcomes trial further showed a 20% reduction in major cardiovascular events.
Mounjaro's clinical programme demonstrated the dual GIP+GLP-1 approach across its own trial series. However, when considering moving from Wegovy to Mounjaro, it's important to note that direct head-to-head comparisons aren't available due to different trial designs and patient populations. Both treatments require clinical assessment to determine suitability, and individual responses may vary regardless of trial outcomes in broader populations.
How Wegovy Works: Understanding the GLP-1 Mechanism
Wegovy's active ingredient, semaglutide, works as a GLP-1 receptor agonist that mimics naturally occurring incretin hormones in your body. When you eat, GLP-1 is normally released from intestinal cells to signal fullness to your brain and slow gastric emptying, creating sustained satiety. Wegovy enhances this natural process by binding to GLP-1 receptors in appetite-controlling brain regions, particularly the hypothalamus. This mechanism may help reduce food cravings and promote feeling full after smaller meals. The once-weekly FlexTouch pen delivers consistent semaglutide levels, maintaining appetite regulation throughout the week. This sustained action explains why Wegovy must be used alongside a reduced-calorie diet and increased physical activity for optimal weight management results.
Moving From Wegovy to Mounjaro: Your Ordering Process
Switching between these treatments begins with our 3-minute online clinical assessment, which captures your medical history, current medications, and weight management goals. Whether you're currently on Wegovy or considering both options, our assessment helps prescribers determine the most suitable treatment path. Standard prescriber review takes 3 working days, though our express service provides 24-hour turnaround for urgent cases. Once approved, your chosen treatment ships via next-day cold-chain delivery, maintaining the 2-8°C storage requirements throughout transit. Our GPhC #9012878 registered pharmacy ensures all medications meet MHRA standards and include comprehensive patient information leaflets for safe self-administration.
Storage and Practical Differences: Wegovy vs Mounjaro
Storage requirements present a key practical difference when moving from Wegovy to Mounjaro. Wegovy offers superior travel flexibility, remaining stable at room temperature (below 30°C) for up to 6 weeks once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. Both require refrigerated storage at 2-8°C before first use, but Wegovy's extended room temperature stability makes it more convenient for frequent travellers or those with limited fridge space. The FlexTouch pen design is user-friendly for once-weekly injections, with clear dosing windows and simple injection technique. Dose escalation with Wegovy follows a structured 4-week pattern through five doses, whilst Mounjaro uses a 6-dose escalation protocol over a longer period.
Wegovy vs Mounjaro: Which Patients Consider Moving Between Treatments
Patients considering moving from Wegovy to Mounjaro typically fall into several categories: those seeking potentially enhanced efficacy through dual receptor targeting, individuals experiencing tolerance or plateau effects, or patients with specific side effect profiles that might respond better to tirzepatide's mechanism. Some patients also consider the switch due to dosing convenience or storage requirements that better fit their lifestyle. The decision should always involve clinical assessment, as both treatments carry specific contraindications and require monitoring.
Conversely, some patients may prefer Wegovy's established GLP-1 mechanism and extensive clinical trial data spanning cardiovascular outcomes. The choice between single and dual receptor agonism isn't simply about efficacy — individual tolerability, injection frequency preferences, and response to dose escalation all influence treatment selection. EverydayMeds provides both options, allowing prescribers to recommend the most appropriate treatment based on comprehensive assessment rather than limited availability.
Complete Your Treatment Decision: Wegovy and Mounjaro Available Now
Both Wegovy and Mounjaro are immediately available through EverydayMeds, eliminating the need to source treatments from multiple pharmacies when comparing options. New customers can apply discount code FIRST40 at checkout, whilst returning patients use DOSE25 for the best available pricing. Our clinical team stands ready to support your decision between these prescription-only medicines, whether you're starting weight management treatment or considering moving from Wegovy to Mounjaro. Express prescriber review and next-day delivery ensure rapid access to your chosen treatment. Visit https://everydaymeds.co.uk/collections/weight-loss to begin your clinical assessment and take control of your weight management journey with expert pharmaceutical support.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
